J C Byrd - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

J C Byrd

Showing results (161-170 of 188) with videos related to

Pageof 19

Sort By:

Leukemia|February 25, 2015

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.

Leukemia|December 17, 2015

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)B Bhatnagar, J S Blachly, J Kohlschmidt, et al.

Leukemia|January 21, 2012

Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapseE Braggio, N E Kay, S VanWier, et al.

Leukemia|October 23, 2009

Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemiaA Sanchez-Aguilera, I Rattmann, D Z Drew, et al.

Leukemia|May 25, 2011

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridolK A Blum, A S Ruppert, J A Woyach, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.

Leukemia|October 8, 2015

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.

Leukemia|January 24, 2014

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerD M Stephens, A S Ruppert, J A Jones, et al.

Blood Cancer Journal|February 4, 2017

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE studyM Montillo, S O'Brien, A Tedeschi, et al.

Leukemia|July 4, 2014

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib responseW E Pierceall, S L Warner, R J Lena, et al.

Pageof 19

Search research articles

Showing results (161-170 of 188) with videos related to

Sort By:

Pageof 19

Leukemia|February 25, 2015

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.

Leukemia|December 17, 2015

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)B Bhatnagar, J S Blachly, J Kohlschmidt, et al.

Leukemia|January 21, 2012

Leukemia|October 23, 2009

Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemiaA Sanchez-Aguilera, I Rattmann, D Z Drew, et al.

Leukemia|May 25, 2011

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridolK A Blum, A S Ruppert, J A Woyach, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001

Leukemia|October 8, 2015

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemiaK A Rogers, A S Ruppert, A Bingman, et al.

Leukemia|January 24, 2014

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerD M Stephens, A S Ruppert, J A Jones, et al.

Blood Cancer Journal|February 4, 2017

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE studyM Montillo, S O'Brien, A Tedeschi, et al.

Leukemia|July 4, 2014

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib responseW E Pierceall, S L Warner, R J Lena, et al.

Pageof 19